MedDay SAS, a France-based biotech, has raised €34 million in a Series B financing round to conduct a confirmatory Phase 3 study in the US of its formulation of biotin in patients with progressive multiple sclerosis (MS). ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
